$DOCS

22 stories mentioning DOCSUpdated 34d ago

Every FINWIRES story that references DOCS, newest first.

What are analysts saying about DOCS?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on DOCS?

Wells Fargo Downgrades Doximity to Underweight From Equalweight, Price Target is $18

Doximity (DOCS)has an average rating of overweight and mean price target of $29.63, according to analysts polled by FactSet.

$DOCS

Sectors37d ago

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.6%.The iShares Biotechnology ETF (IBB) climbed 2%.In corporate news, Doximity (DOCS) reported higher fiscal Q1 revenue late Thursday, beating consensus but adjusted earnings missed estimates. On the company's post-earnings conference call, per a FactSet transcript, Chief Executive Jeffrey Tangney said the revenue that Doximity's new AI search tool is generating is 10 times what it costs to run. Doximity shares surged 36%.Pulse Biosciences (PLSE) shares jumped past 9% in Friday trading, a day after the company reported its Q2 results.Neurocrine Biosciences (NBIX) shares gained 2.8% after the company said Friday it has started a phase 1 first-in-human trial of NBIP-1968, an experimental drug for obesity.ANI Pharmaceuticals (ANIP) shares were down 5.9% even after it posted higher Q2 adjusted earnings and net revenue.

$ANIP$DOCS$NBIX$PLSE

Wire37d ago

Top Midday Gainers

Doximity (DOCS) reported higher fiscal Q1 revenue late Thursday, beating consensus but adjusted earnings missed estimates. On the company's post-earnings conference call, per a FactSet transcript, Chief Executive Jeffrey Tangney said the revenue that Doximity's new AI search tool is generating is 10 times what it costs to run.Shares soared 33% amid a surge in intraday trading volume to over 43.1 million from a daily average of about 4.16 million.Airbnb's (ABNB) Q2 earnings and sales surpassed analysts' estimates, per results released late Thursday, amid the FIFA World Cup-led strong demand.Shares jumped 15%, with intraday trading volume rising to more than 10.6 million from the stock's daily average of about 3.8 million.Cloudflare (NET) shares jumped 7.4% amid heavy trading after the company reported overnight stronger-than-expected Q2 results and raised its 2026 guidance.More than 5.78 million shares of the company traded intraday compared with a daily average of about 3.84 million.Price: $27.45, Change: $+6.79, Percent Change: +32.87%

$ABNB$DOCS$NET

Wire37d ago

Doximity Raises FY27 Outlook on AI Search Momentum, RBC Says

Doximity (DOCS) posted a strong fiscal Q1, with revenue growth reaccelerating on AI-driven client engagement in its legacy business and a guidance raise that indicates early commercial traction from AI search for fiscal 2027, RBC Capital Markets said Thursday in a report.While net revenue retention trends and margin investment warrant monitoring, RBC said record user engagement, a strengthening competitive position and a growing AI revenue pipeline support its view of a fiscal 2028 reacceleration.The company attributed Q1 revenue outperformance to two pharma-specific drivers, including AI search lifting client engagement across the portfolio and a meaningful rebound from a top-20 customer that had previously pulled back, RBC said.New search contracts are supporting the increase in fiscal 2027 revenue guidance, with most of the contracted AI revenue expected in fiscal Q3 as the focus shifts to larger, longer-duration deals during the upfront sales cycle, the report said.RBC maintained its outperform rating on Doximity stock and its $28 price target.Doximity surged 36% in Friday trading. CEO Jeffrey Tangney said revenue from the company's new AI search tool is running at 10 times its operating cost.Price: $28.05, Change: $+7.39, Percent Change: +35.77%

$DOCS

Wire37d ago

Doximity's AI Pivot Clouds Growth Trajectory, May Face Execution Risks, BofA Says in Downgrade

Doximity (DOCS) faces limited clarity on the near-term path of revenue and margins, as well as execution risks tied to its shift into an artificial intelligence-powered platform for healthcare professionals, BofA Securities said Monday.The digital platform, which dominates the pharmaceutical advertising targeting physicians, is "making the right strategic investments" as it competes with AI-focused entities such as OpenAI and OpenEvidence, BofA analyst Allen Lutz said in a note to clients. Doximity's offerings include a new a new AI assistant for physicians called DoxGPT."Given the deep pockets of these peers and the fact that top 20 pharma already spends significantly with Doximity, we have some concerns around (Doximity's) ability to grow its current allocations as well as successfully compete for AI dollars," Lutz said.The brokerage downgraded its rating on the Doximity stock to underperform from buy and reduced the price target to $20 from $38. "While shares are inexpensive, we see downside risk to consensus over the next few years," Lutz wrote.The company's shares were down 2.7% in Monday afternoon trade. The stock has lost 54% in value so far this year."We anticipate Doximity's emerging investment cycle to go on for multiple years and could include more significant investments than investors currently appreciate," Lutz said. "With current margins still near 50%, we think it is not unreasonable to expect Doximity to spend more money for a longer period of time, which could weigh on margins."The company may need to lower its prices to support sales, according to the note. "Together, we see structural pressure to Doximity's industry-leading margin profile," Lutz said.BofA lowered its 2027 and 2028 revenue outlook for Doximity."We anticipate pharma manufacturers will continue to diversify spend across AI competitors in the coming years, which is likely to limit Doximity's share gains," Lutz said. "This leaves Doximity more reliant on (healthcare professional) pharma market growth and the trajectory of pharma ad-spend allocation."Price: $20.23, Change: $-0.65, Percent Change: -3.11%

$DOCS

Research76d ago

Update: BofA Downgrades Doximity to Underperform From Buy, Cuts Price Target to $20 From $38

(Updates with the analyst's commentary.)BofA Securities downgraded Doximity (DOCS) to underperform rating from buy and cut its price target to $20 from $38.The brokerage attributes the downgrade to "limited clarity" on near-term revenue/margins movement and "execution risks" from the company's pivot to artificial intelligence (AI).While BofA believes Doximity is "making the right strategic investments," the brokerage has "some concerns" over the firm's capability "to grow its current allocations" and to compete in the AI space.Doximity has an average rating of overweight and mean price target of $24.27, according to analysts polled by FactSet.Price: $20.63, Change: $-0.25, Percent Change: -1.20%

$DOCS

Wire76d ago

Doximity Facing Limited Clarity on AI Projects, BofA Says

Doximity (DOCS) is facing limited clarity on the execution risks linked to its pivot to artificial intelligence as well as on the near-term trajectory of its revenue and margins, BofA Securities said in a note Monday.The company is the "industry leader in pharma advertising to physicians" and is also "making the right strategic investments to compete against emerging AI models" like OpenEvidence and OpenAI, according to the note.However, given that the company's AI peers have "deep pockets" and the top 20 pharma companies already spend significantly with Doximity, there are concerns surrounding Doximity's "ability to grow its current allocations as well as successfully compete for AI dollars," BofA said.The investment firm also said that since Doximity's earnings before interest, taxes, depreciation, and amortization margin profile is near 50%, investors may be underappreciating the duration and size of the company's future investments."While shares are inexpensive, we see downside risk to consensus over the next few years," the firm said.BofA downgraded Doximity to underperform from buy and cut the company's price target to $20 from $38.Price: $20.61, Change: $-0.27, Percent Change: -1.29%

$DOCS

Research76d ago

BofA Downgrades Doximity to Underperform From Buy, Price Target is $20

Doximity (DOCS) has an average rating of overweight and mean price target of $24.27, according to analysts polled by FactSet.

$DOCS

Wire80d ago

Doximity Faces Continued Softness in Pharma Marketing Spending, RBC Capital Markets Says

Doximity (DOCS) expects continued softness in pharmaceutical marketing spending through at least fiscal Q1 and Q2, while it will likely benefit from some artificial intelligence revenue contribution in fiscal Q3, RBC Capital Markets said in a note Wednesday.The brokerage, which hosted investor meetings with the company, said it came away cautious on the company's near-term outlook, but noted greater visibility on opportunities for revenue growth toward H2 of fiscal 2027 and more materially into fiscal 2028 from capturing more spend into its AI tools.The company believes its AI offering is better positioned with large pharmaceutical partners seeking alternatives to programmatic, biddable advertising models, according to the note.RBC has an outperform rating on the stock and a $28 price target.Shares of Doximity were down 3.5% in Thursday trading.Price: $20.11, Change: $-0.72, Percent Change: -3.46%

$DOCS

Sectors122d ago

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Thursday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) fractionally higher.The iShares Biotechnology ETF (IBB) decreased 0.7%.In corporate news, Prestige Consumer Healthcare's (PBH) officials said Thursday that weak eye care sales and a difficult consumer backdrop drove disappointing fiscal Q4 results at the consumer healthcare products company. Its shares were down past 11%.Biogen (BIIB) shares fell nearly 7% after the firm said Thursday that a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding AI opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note. Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating. Doximity shares dropped more than 23%.Aveanna Healthcare (AVAH) shares jumped past 8% after it reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.

$AVAH$BIIB$DOCS$PBH

Wire122d ago

Top Midday Decliners

Doximity (DOCS) reported overnight lower fiscal Q4 adjusted earnings and issued fiscal Q1 and full-year 2027 revenue guidance below analysts' estimates.Multiple analysts also downgraded their respective ratings on the company's stock.Shares sank 25% following a surge in intraday trading volume to over 17.9 million from a daily average of about 3.08 million.Live Ventures (LIVE) swung to a net loss in fiscal Q2 as sales slipped from a year ago.Shares slumped 25% as intraday trading volume advanced to more than 41,000 from a daily average of about 5,000.Aeluma (ALMU) reported Wednesday a swing to a fiscal Q3 loss and a year-over-year drop in revenue.Shares dropped 17%, with intraday trading volume at over 4.52 million versus a daily average of about 1.35 million.Price: $17.48, Change: $-5.91, Percent Change: -25.27%

$ALMU$DOCS$LIVE

Sectors122d ago

Sector Update: Healthcare Stocks Softer Thursday Afternoon

Healthcare stocks edged down Thursday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) decreased 0.5%.In corporate news, Biogen (BIIB) shares fell nearly 6% after the firm said Thursday that a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.Prestige Consumer Healthcare (PBH) reported weaker-than-expected Q4 results and issued 2026 guidance below consensus, with the shortfall driven primarily by supply constraints in Clear Eyes and broader execution pressures, Oppenheimer said in a note. Oppenheimer downgraded the stock to perform from outperform and removed its $65 price target. Prestige shares slumped past 8%.Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding AI opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note. Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating. Doximity shares dropped more than 24%.Aveanna Healthcare (AVAH) shares jumped 11% after it reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.

$AVAH$BIIB$DOCS$PBH

Wire122d ago

Doximity Growth Slowdown, Weak Outlook Raise Concerns, Morgan Stanley Says

Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding artificial intelligence opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note Thursday.The company reported fiscal Q4 revenue of $145 million, up 5% from a year earlier and slightly above Wall Street estimates. However, the company guided fiscal Q1 revenue below Wall Street estimates and forecast fiscal 2027 revenue growth of 4% at the midpoint, disappointing analysts who expected stronger trends in the healthcare digital advertising market, according to the note.The investment firm said the stock could remain in the "penalty box" in the near term, as it cited several "positives that will likely get overlooked," including a roughly 30% increase in active prescribers using Doximity's workflow tools to more than 800,000 users.The firm also cited early traction for the company's AI search product, which won deals with top pharmaceutical companies within weeks of launch.Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating.Shares of Doximity were falling more than 26% in late morning trading Thursday.Price: $17.24, Change: $-6.15, Percent Change: -26.29%

$DOCS

Commodities122d ago

Exchange-Traded Funds, Equity Futures Advance Pre-Bell Thursday Amid US-China Meeting

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively traded Invesco QQQ Trust (QQQ) was 0.2% higher in Thursday's premarket activity amid a two-day meeting between the US and China.US stock futures were also higher, with S&P 500 Index futures up 0.3%, Dow Jones Industrial Average futures advancing 0.7%, and Nasdaq futures gaining 0.2% before the start of regular trading.US initial jobless claims rose to a level of 211,000 in the week ended May 9 from a downwardly revised 199,000 level in the previous week, compared with expectations for a smaller increase to 205,000 in a survey of analysts compiled by Bloomberg.US import prices rose by 1.9% in April, above the 1% increase expected in a survey compiled by Bloomberg as of 7:35 am ET and faster than a 0.9% gain in March.US retail sales rose by 0.5% in April, as expected in a survey compiled by Bloomberg as of 7:35 am ET and following the previous month's 1.6% gain.Business inventory data for March is due to be released at 10 am ET, followed by weekly natural gas stocks at 10:30 am ET.Federal Reserve Kansas City President Jeffrey Schmid, Cleveland President Beth Hammack, New York President John Williams, and Governor Michael Barr are slated to speak on Thursday.In premarket action, bitcoin was down by 10%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.2% lower, Ether ETF (EETH) advanced 0.2%, and Bitcoin & Ether Market Cap Weight ETF (BETH) retreated by 0.01%.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.2%. The Vanguard Health Care Index Fund (VHT), the iShares US Healthcare ETF (IYH), and the iShares Biotechnology ETF (IBB) were flat.Doximity (DOCS) stock was down more than 10% premarket after the company overnight reported a steeper-than-expected drop in fiscal Q4 adjusted earnings and sales guidance for the next financial year lagged market expectations.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) gained by 0.4%, and the iShares US Technology ETF (IYW) was 0.5% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 0.7%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 0.3%, while the iShares Semiconductor ETF (SOXX) fell by 0.1%.Cisco Systems (CSCO) shares were up more than 15% in premarket activity after the company reported forecast-beating fiscal Q3 results and said it plans to lay off about 4,000 employees, representing around 5% of its workforce.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.1%, and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) gained 0.3%. The iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increased by 0.3%. The VanEck Retail ETF (RTH) retreated by 0.01%, while the State Street SPDR S&P Retail ETF (XRT) was 0.3% higher.Yeti (YETI) shares were up more than 10% pre-bell after the company reported better-than-expected fiscal Q1 adjusted net income and net sales.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated by 0.2%, while the Vanguard Industrials Index Fund (VIS) gained 0.04% and the iShares US Industrials ETF (IYJ) was inactive.Copa (CPA) stock was up more than 3% before the opening bell after the company reported higher Q1 earnings and operating revenue.EnergyThe iShares US Energy ETF (IYE) was down 0.3%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.02%.Consolidated Edison (ED) stock was down more than 2% before the opening bell. Goldman Sachs raised its price target on the company to $105 from $103 and maintained its sell rating.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.4%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.9%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.8% lower.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 0.1% to $100.95 per barrel on the New York Mercantile Exchange. Natural gas was down 0.7% to $2.84 per 1 million British Thermal Units. The United States Oil Fund (USO) decreased by 0.7%, while the United States Natural Gas Fund (UNG) was flat.Gold futures for May retreated by 0.1% to $4,700.30 an ounce on the Comex. Silver futures fell by 2.3% to $87.30 an ounce. SPDR Gold Shares (GLD) was 0.2% higher, and the iShares Silver Trust (SLV) declined by 0.8%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$CPA$CSCO$DOCS$ED$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$PMR$QQQ$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD$YETI

Research122d ago